Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Access content directly
Journal Articles Frontiers in Pharmacology Year : 2021

Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation

Abstract

Background and Purpose: Several formulations of tacrolimus are available, but evidence of the benefit of changing to the most recent formulations is lacking. Tacrolimus intrapatient variability (tacrolimus IPV) is an emerging risk factor associated with poor graft outcomes after solid organ transplantations. Here, we examined the modifications of tacrolimus IPV after switching to a different formulation of tacrolimus. Experimental Approach: We identified 353 solid organ transplant recipients that were switched in our center from immediate-release (IR-tacrolimus) or prolonged-release tacrolimus (PR-tacrolimus) to extended-release, LCP-tacrolimus (LCP-tacrolimus). Among them, 54 patients underwent at least 3 available tacrolimus blood concentrations before and after the switch, allowing us to investigate tacrolimus IPV.
Fichier principal
Vignette du fichier
2021_Del Bello_Frontiers pharmacology- Tacrolimus intrapatient.pdf (1.16 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive
Licence

Dates and versions

hal-03623073 , version 1 (29-03-2022)

Licence

Identifiers

Cite

Arnaud del Bello, Clotilde Gaible, Nathalie Longlune, Anne-Laure Hebral, Lauren Esposito, et al.. Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation. Frontiers in Pharmacology, 2021, 12, ⟨10.3389/fphar.2021.602764⟩. ⟨hal-03623073⟩
45 View
25 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More